Skip to main content

Bausch Health Companies Inc(BHC-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low7.00
Day High7.24
Open:7.07
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
ACCESSWIRE
The Absence of an Overt Hepatic Encephalopathy (OHE)-Specific Diagnosis Code May Result in Increased OHE-Related Length of Stay and Hospitalization-Related Costs Due to OHE Rate Underestimation, According to New Analysis
ACCESSWIRE
CORRECTION BY SOURCE: The Absence of an Overt Hepatic Encephalopathy (OHE)-Specific Diagnosis Code May Result in Increased OHE-Related Length of Stay and Hospitalization-Related Costs Due to OHE Rate Underestimation, According to New Analysis
ACCESSWIRE
As Daylight Saving Time Comes to a Close, Bausch Health Champions Mental Health with a Spotlight on Preventing Seasonal Affective Disorder (SAD)
ACCESSWIRE
Bausch Health Announces Third-Quarter 2023 Results
ACCESSWIRE
U.S. District Court Dismisses Norwich's Lawsuit Against the FDA
ACCESSWIRE
Bausch Health Unveils "Looking Forward" - A New DTC Television Campaign for Seasonal Affective Disorder (SAD)
ACCESSWIRE
FDA Approves Cabtreo(TM) (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide) Topical Gel for the Treatment of Acne Vulgaris in Patients Twelve Years of Age and Older
ACCESSWIRE
New Analysis Indicates That a Majority of Overt Hepatic Encephalopathy (OHE) Patients May Face Delays in Treatment Initiation and Gaps During Treatment for Access to Treatment Indicated to Reduce Risk for OHE Recurrence
ACCESSWIRE
Bausch Health to Announce Third-Quarter 2023 Results on Nov. 2
ACCESSWIRE
Salix Pharmaceuticals Releases Liver Health Annual Trends Report Identifying Increase in Chronic Liver Disease and Cirrhosis-Related Deaths Marking These as Ninth Leading Cause of Death in U.S.
ACCESSWIRE
Salix Pharmaceuticals Partners with Bellamy Young
ACCESSWIRE
Bausch Health's Bausch + Lomb Announces Completion of the Acquisition of XIIDRA(R)
TheNewswire.com
BHC FINAL DEADLINE ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Bausch Health Companies Inc. Investors to Secure Counsel Before Important September 25 Deadline in Securities Class Action - BHC
PR Newswire
BHC Investors Have Opportunity to Lead Bausch Health Companies Inc. Securities Fraud Lawsuit
PR Newswire
BHC DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Bausch Health Companies Inc. Investors to Secure Counsel Before Important September 25 Deadline in Securities Class Action - BHC
PR Newswire
BHC Investors Have Opportunity to Lead Bausch Health Companies Inc. Securities Fraud Lawsuit
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch Health Companies Inc. - BHC
PR Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Bausch Health Companies Inc.(BHC) Investors of a Class Action Lawsuit and Upcoming Deadline
ACCESSWIRE
League of United Latin American Citizens (LULAC) Joins OraPharma in the Fight Against Gum Disease
Motley Fool
Why Bausch Health Stock Is Jumping Today
Motley Fool
Why Shares of Bausch Health Companies Fell Tuesday
TheNewswire.com
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Bausch Health Companies Inc. Investors with Losses to Secure Counsel Before Important September 25 Deadline in Securities Class Action - BHC
ACCESSWIRE
Bausch Health Announces CFO Transition Plan
PR Newswire
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Bausch Investors of a Lead Plaintiff Deadline of September 25, 2023
TheNewswire.com
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Bausch Health Companies Inc. Investors to Secure Counsel Before Important September 25 Deadline in Securities Class Action - BHC
PR Newswire
BHC Investors Have Opportunity to Lead Bausch Health Companies Inc. Securities Fraud Lawsuit
PR Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Bausch Health Companies Inc.(BHC) Investors of a Class Action Lawsuit and Upcoming Deadline
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch Health Companies Inc. - BHC
ACCESSWIRE
New Bausch Health Treatment PrUCERIS(R) (budesonide) Aerosol Foam Now Available Across Canada to Treat Mild to Moderate Distal Ulcerative Colitis in Adults
TheNewswire.com
ROSEN, A TOP RANKED LAW FIRM, Encourages Bausch Health Companies Inc. Investors to Secure Counsel Before Important September 25 Deadline in Securities Class Action - BHC
PR Newswire
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Bausch Investors of a Lead Plaintiff Deadline of September 25, 2023
ACCESSWIRE
Bausch Health's Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA(R)

Profile

Bausch Health Companies Inc. develops, manufactures and markets a wide array of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products along with medical devices such as contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices in the therapeutic areas of eye-health, gastroenterology (GI), and dermatology.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2023.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2023 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.